The aggregate proceeds of the company’s IPO and private placement were $24 million. The proceeds will be used to finance Check-Cap’s clinical program, product development and corporate purposes.
The company’s shares began trading on the NASDAQ Capital Market on Feb. 19 under the ticker symbol “CHEKI.”
The company’s product is a preparation-free, ingestible imaging capsule designed for colorectal cancer screening.
More articles on gastroenterology:
AGA to hold workshop on effective scope cleaning
RD Biomed to launch study in China to examine reflux disease diagnostic device
Dr. Amar Naik joins Loyola University Health System
